Sai Parenterals Ltd
Sai Parenterals Q2 Results 2026 (FY27): Revenue ₹196.1 Cr, EBITDA margin 17.6%
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Guidance rank: #78 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Sai Parenterals Ltd Q2 FY27 key numbers
- Revenue
- Q2FY27 Revenue from Operations: ₹196.1 crore, up 257.4% YoY from ₹54.9 crore in Q2FY26.
As stated in Sai Parenterals Ltd's Q2 FY27 investor presentation · published 1 Nov 2026. Reported figures, not investment advice.
Based on Sai Parenterals Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2FY27 Revenue from Operations: ₹196.1 crore, up 257.4% YoY from ₹54.9 crore in Q2FY26 (Page 56). Q2FY27 Financials: - EBITDA: Rs.
From Sai Parenterals Ltd's Q2 FY27 earnings-call transcript · updated 1 Nov 2026.
Revenue & Sales Performance
- Q2FY27 Revenue from Operations: ₹196.1 crore, up 257.4% YoY from ₹54.9 crore in Q2FY26 (Page 56).
- H1FY27 Revenue: ₹376 crore, up 321.0% YoY from ₹89.3 crore in H1FY26 (Page 55 and 56).
- Sequential growth: Q2FY27 revenue grew 9% QoQ from ₹179.9 crore in Q1FY27 (Page 56).
- Gross margin rose sequentially from 40.9% to 47.5% in Q2FY27, indicating improved sales efficiency (Page 48).
- Capacity expansion: Unit III increased capacity from 85.5 to 155 million units/month, with output ramp-up starting Q4FY27 (Page 48).
- The Adelaide facility in Australia begins operations January 2027; commercial supply expected April 2027 (Page 48).
2 more points from Sai Parenterals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Sai Parenterals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Total capex: Rs. 571 crore across four projects; Rs. 440 crore funded by the company
- Unit III and Unit IV upgrades: Rs. 27 crore; Unit III expansion completed; Unit IV EU-GMP upgrade targeted for January 2027
- Indian injectable and oral capacity: Rs. 83.83 crore for 60% stake in Saicriti Pharma’s Rs. 215 crore injectable facility outside ORR; completion expected July 2027
- R&D centre: Rs. 15 crore for 60% stake in Prathyak Laboratories at Genome Valley; acquisition completed October 5, 2026
- Adelaide, Australia facility: Rs. 311 crore (AUD 53 million) for manufacturing tablets, liquids, nasal sprays, creams; TGA licensing expected by March 31, 2027
2 more points from Sai Parenterals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sai Parenterals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Sai Parenterals Ltd said on order book & pipeline — free account, 30 seconds.
Sai Parenterals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹195 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sai Parenteral's's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- P & G Health Ltd (Q2 FY27)
Revenue from Operations for the quarter ended September 30, 2026, is ₹38,249 lakhs (Page 4). Key results statement takeaways from Procter & Gamble Health Ltd's
- Akums Drugs (Q2 FY27)
Q2 FY27 revenue reported at ₹1,342 crore, up 31.9% YoY from ₹1,018 crore in Q2 FY26 (Page 12, 10). Key investor presentation takeaways from Akums Drugs & Pharma
- Accretion Pha. (Q2 FY27)
25.85% increase) . Key results statement takeaways from Accretion Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Sigachi Indust. (Q2 FY27)
Year-on-Year (YoY) Revenue Growth: 18.09% (Q2 FY27 vs Q2 FY26) . Key investor presentation takeaways from Sigachi Industries Ltd's Q2 FY27 investor presentation
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Sai Parenterals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sai Parenterals Ltd Q2 FY27 results?
Q2FY27 Revenue from Operations: ₹196.1 crore, up 257.4% YoY from ₹54.9 crore in Q2FY26 (Page 56). Q2FY27 Financials: - EBITDA: Rs.
What is Sai Parenterals Ltd share price analysis?
Sai Parenterals Ltd currently shows a neutral. The stock trades at a P/E of 111.1 with a market cap of ₹2,307 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sai Parenterals Ltd planning capital expenditure?
Total capex: Rs.
Keep Sai Parenterals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.